Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia

Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia

The PI3K/Akt pathway—and in particular PI3Kδ—is known for its role in drug resistant B-cell acute lymphoblastic leukemia (B-ALL) and it is often upregulated in refractory or relapsed B-ALL. Myc proteins are transcription factors responsible for transcribing pro-proliferative genes and c-Myc is often...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Yongsheng Ruan, Hye Na Kim, Heather A. Ogana, Zesheng Wan, Samantha Hurwitz, Cydney Nichols, Nour Abdel-Azim, Ariana Coba, Seyoung Seo, Yong-Hwee Eddie Loh, Eun Ji Gang, Hisham Abdel-Azim, Chih-Lin Hsieh, Michael R. Lieber, Chintan Parekh, Dhananjay Pal, Deepa Bhojwani, Donald L. Durden, Yong-Mi Kim
Format: article
Langue:EN
Publié: Frontiers Media S.A. 2021
Sujets:
PI3Kδ
p-AKT
BRD4
c-Myc
acute lymphoblastic leukemia
SF2535
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Accès en ligne:https://doaj.org/article/9d2a16f695cc4722b8574521dd391e56
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/9d2a16f695cc4722b8574521dd391e56

Documents similaires